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Aims/background: To evaluate the correlation between protein S100B concentrations 
measured in the jugular bulb as well as at peripheral level and the prognostic 
usefulness of this marker.    
Methods: A prospective study of all patients admitted to the intensive care unit with 
acute brain damage was carried out. Peripheral and jugular bulb blood samples were 
collected upon admission and every 24 hours for three days. The endpoints were brain 
death diagnosis and the Glasgow Outcome Scale score after 6 months.  
Results: A total of 83 patients were included. Jugular protein S100B levels were 
greater than systemic levels upon admission and also after 24 and 72 hours (mean 
difference >0). Jugular protein S100B levels showed aceptable precision in predicting 
brain death both upon admission [AUC 0.67 (95% CI 0.53-0.80)] and after 48 hours 
[AUC 0.73 (95% CI 0.57-0.89)]. Similar results were obtained regarding the capacity of 
jugular protein S100B levels upon admission to predict an unfavourable outcome 
(AUC 0.69 (95% CI 0.56-0.79)). The gradient upon admission (jugular-peripheral 
levels) showed its capacity to predict the development of brain death [AUC 0.74 (95% 
CI 0.62-0.86)] and together with the Glasgow Coma Scale constituted the independent 
factors associated with the development of brain death.    
Conclusion: Regional protein S100B determinations are higher than systemic 
determinations, thus confirming the cerebral origin of protein S100B. The transcranial 
protein S100B gradient is correlated to the development of brain death. 
Key words: Neurocritical care. Serum S100B. Acute brain injury. Brain injury 



















Acute brain damage has a high prevalence, produces important morbidity and 
mortality which in turn have important socioeconomic consequences [1,2]. The 
physiopathology of brain damage is dynamic over time, encompasses different 
pathways and changes according to the evolutive stage involved [3]. This may explain 
why there have been few advances in the management of such patients. Many of the 
studies in this field have been of an experimental nature and transference to a clinical 
setting has been characterized by small studies - multicentre trials limited by the 
heterogeneity of the patients included.  
In the last decade there has been growing interest in the development of brain 
damage biomarkers that may become tools for guiding treatment, monitoring the 
clinical course and assessing patient prognosis [4]. In this context, different proteins 
have been investigated in urine, cerebrospinal fluid and serum. However, the results 
have not been as promising as expected. Protein S100B binds to calcium and plays a 
neurotrophic role at both intra and extracellular level. It is glia-speific and is essentially 
expressed by astrocytes, though it can also be produced by other types of cells such 
as adipocytes, chondrocytes, myocytes, in addition to melanoma and glioblastoma 
cells [5-8]. These extracerebral sources therefore may limit its usefulness as a marker. 
Protein S100B has been proposed as a marker of structural brain damage with 
potential prognostic applications. Studies have been made of its correlation to clinical 
outcome [9-17], the extent of damage [18], patient quality of life after brain damage 
[19] and the neuropsychological sequelae [19,20]. Likewise, studies have been carried 















correlate it to patient prognosis [15]. Nevertheless, results have been inconclusive and 
even contradictory [21].  
The explanation for this is that the studies carried out to date are characterized by 
heterogeneity of brain damage and of its severity, diversity in the biological samples 
used and differences in the timing of sample collection. The vast majority of studies 
have used serum samples, urine samples or even cerebrospinal fluid samples yet few 
evaluations have been made of the concentration of S100B in cerebral venous 
samples obtained with catheters located in the region of the jugular bulb [22]. The 
importance of such samples is that they come directly from venous drainage of the 
brain, without interferences from other extracranial sources. One recent paper has 
explored the brain specificity of this protein. Pharm et al suggested that this effect is 
relatively insignificant, but further studies are required to end the controversy [23]. 
Thus the dilemma continues. Other possible markers of brain damage such as IL6 
have also been evaluated in jugular samples. In this context, regional determinations 
were found to be significantly superior to peripheral samples and the jugular-peripheral 
gradient was found to be correlated to patient prognosis [24,25]. 
 
With the aim of defining the role of protein S100B obtained from cerebral  venous 
drainage as a prognostic predictor following acute brain damage, the present study 
was designed to evaluate the hypothesis that regional samples yield higher protein 
S100B levels. The following specific objectives were established: 1) to determine 
whether there are differences in the levels of protein S100B according to the origin of 
the samples (peripheral samples obtained from the central venous catheter or regional 
samples obtained from the jugular bulb); 2) to assess the kinetic profiles of both 
determinations; and 3) to determine whether the gradient is correlated to prognosis 


















Material and methods 
Patients 
A prospective observational study was made of patients with serious acute brain 
damage admitted to the Intensive Care Service in “Marqués de Valdecilla” University 
Hospital (Santander, Spain). This is  a tertiary level hospital with a 30-bed Intensive 
Care Unit (ICU). Patients with serious acute brain damage (head injuries or cerebral 
haemorrhage) were enrolled based on the following inclusion criteria: Glasgow Coma 
Scale score (GCS) < 9, Marshall score ≥ 3, need for mechanical ventilation, age > 14 
years, blood sampling less than 8 hours after brain damage, haemodynamic stability 
(no shock or cardiac arrest) and the exclusion of extracranial injuries and immune 
diseases. 
The hospital Ethics Committee approved the study and informed consent was 
obtained from patient relatives before inclusion in the study. 
 
Study data 
Patient data were recorded upon admission to the ICU and consisted of gender, age, 
pupillary response (pupillary light reflex positive in both eyes and symmetric pupils 
were considered normal, whereas other presentations were considered abnormal) and 
the Acute Physiology and Chronic Health Evaluation (APACHE) II score [26]. GCS 
determined by emergency services was considered. Brain death was diagnosed 
according to the clinical and legal criteria of Spanish law. Outcome at 6 months based 
on the Glasgow Outcome Score (GOS) was determined in all patients [27]. GOS was 















disability) was regarded as an unfavourable outcome, and GOS 4-5 (moderate 
disability or good recovery) as a favourable outcome. The scores were determined by 
telephone call to patient relatives or by visiting patients in the rehabilitation ward of our 




Blood samples from the jugular bulb (regional sera), and those collected with a central 
venous catheter (systemic samples), were obtained simultaneously upon admission to 
ICU, and also 24, 48 and 72 hours after brain damage. A fiberoptic catheter (5F; 
Opticath 5, Abbott Laboratories, North Chicago, IL, USA) was routinely inserted into 
the jugular bulb on the dominant side, i.e. on the homolateral side in focal injuries 
[28,29]. This catheter was inserted for routine clinical management and the correct 
position was confirmed with lateral or AP neck X-ray. Samples were allowed to clot at 
room temperature and were centrifuged at 3,000 rpm for 10 minutes to separate the 
sera which in turn were stored at -40 ºC until use.  
 
Measurement of protein S100B 
Serum concentration of protein S100B was measured with an 
electrochemoluminescence test produced by Elecsys 2010 immunoassay systems 
(Roche Diagnostics, Mannheim, Germany). Technical specifications of the 
manufacturer were followed, requiring 18 minutes and a minimum of 20 μl of serum for 
testing purposes. The lower and upper limits of detection are 0.005-39 μg/l. Values of 
< 0.105 μg/l are regarded by the manufacturer as normal, based on previous studies 



















Categorical variables were described using absolute value and corresponding 
percentage. Continuous variables were expressed as median and interquarti le range 
(IQR). The Kolmogorov-Smirnov test was used to identify variables with normal 
distribution. The Spearman correlation test was used to explore the relationship 
between regional and systemic determinations. 
Numerical values between groups were compared using the Mann-Whitney U-test, 
with application of the chi-squared test in the case of categorical data.  
Friedman’s ANOVA was conducted for repeated measures to compare differences 
between the two GOS groups (unfavourable/favourable outcome) in the four S100B 
samples. Univariate and multivariate logistic regression analysis was performed to 
assess the prognostic capacity (unfavourable outcome and the development of brain 
death) of the clinical variables and determination of protein S100B.  
Receiver operating characteristic curves were used to establish the optimum cut-off 
points and the sensitivity and specificity of the different determinations at different 
timepoints. The areas under the curve (AUC) of the different protein S100B 
determinations were compared using the method described by Hanley and McNeil  
[32]. Statistical significance was considered for p < 0.05. The SPSS version 15.0 




The study comprised 83 patients (26 women and 57 men) with a diagnosis of 















All patients with traumatism had a Marshall score of ≥ 3 according to the computerized 
axial tomography findings. Table 1 shows demographic and clinical data of the 
patients included in the study. Bulb catheter placement was easy to perform and 
successful in all patients. This intervention required no additional time to be carried out. 
Mortality rate at 6 months was 55.4% (46 patients), and after this period of time 26.5% 
of patients showed favourable outcome (GOS 4 and 5). Brain death was diagnosed in 
25 patients (30.1%). In 14 cases brain death was diagnosed in the first 72 hours. 
The time course of protein S100B determinations is shown in Table 2. Two elevations 
(in regional samples) were recorded at the time of admission and 48 hours after brain 
damage (Figure 1). Regional and peripheral determinations showed significant 
correlations at all timepoints (r > 0.7; p < 0.001). 
There were no differences in protein S100B values in relation to patient gender, age, 
type of brain damage and neurosurgical procedure at any of the timepoints in the 
regional or systemic samples (p > 0.05). Patients yielding an unfavourable outcome 
(GOS 1-3 or the development of brain death) were significantly older and in a worse 
serious condition (neurological and systemic). Likewise, protein S100B transcranial 
gradient upon admission was significantly greater in patients who developed brain 
death (Table 3). 
 
Diagnostic capacity of protein S100B determinations 
Gradient upon admission showed a significant capacity to predict the development of 
brain death [area under the ROC curve 0.739 (95% CI 0.618-0.859), p = 0.002). In 
relation to diagnosis of brain death, peripheral determinations upon admission, after 48 
and 72 hours showed areas under the ROC curve of > 0.6 (Figure 2). Areas of > 0.6 















of unfavourable outcome (GOS 1-3), the areas under the ROC curves of the peripheral 
and regional samples upon admission and after 24 and 48 hours were > 0.6 (Figure 2). 
In relation to diagnosis of both brain death and poor prognosis, no significant 
differences were recorded on comparing ROC curves of peripheral and regional 
determinations at different timepoints (p>0.05).  
Table 4 shows the optimum cut-off points of protein S100B determinations and of the 
transcranial gradient in diagnosing development of brain death, according to the 
criterion of maximum sensitivity and specificity.  
Univariate and multivariate analyses were made of the development of brain death, 
considering the main study variables (age, GCS, APACHE II, pupillary alterations and 
transcranial gradient upon admission), with statistically significant results for all of 
them. Multivariate analysis proved significant for GCS (OR 0.7, 95% CI 0.53-0.97, p = 
0.017) and transcranial gradient upon admission (OR 7.16, 95% CI 1.42-36.0; p = 
0.001). 
However, on performing the analysis with respect to unfavourable outcome at 6 
months, patient age (OR 1.055, 95% CI 1.013-1.099, p = 0.006) and the APACHE II 




This is the first study to simultaneously measure and compare protein S100B levels in 
regional venous blood in the brain (jugular bulb) and in systemic venous blood. To our 
knowledge, no other study has attempted to correlate systemic venous determinations 
to those obtained in cerebral venous blood samples, which offer more reliable 
information regarding changes occurring in the brain as a result of damage. Some 















[22,33]. No evaluations of the release profile in samples from the brain, which is where 
the protein is produced, have been made to date. This circumstance may have 
adversely conditioned previous studies, since extracranial protein S100B sources may 
limit the usefulness of peripheral determinations. One of the desirable characteristics 
of any potential marker is good accessibility with respect to both the technique 
required and to the biological sample involved. In the case of brain damage, the use o f 
peripheral blood samples would be ideal; however, since protein S100B can come 
from sources other than the brain, it is of interest to contrast peripheral determinations 
and measurements obtained directly from venous drainage of the brain. Our results 
confirm that protein S100B levels are higher in the jugular bulb samples and indicate 
good correlation between the two types of samples (regional and systemic). This fact 
ratifies the brain origin of the protein after brain damage, and shows that it meets one 
of the required criteria of a biomarker: specificity of the affected organ. The above in 
turn confirms the validity of the peripheral determinations of protein S100B in this 
patient cohort. The results obtained thus support the routine use of such 
determinations, since the obtainment of peripheral samples is feasible at any 
healthcare level, while regional measurements (jugular bulb catheter) or the need for 
cerebrospinal fluid samples are not available in all centres, pose accessibility problems, 
and are typically restricted to a research setting. 
 
In addition, our findings corroborate the existence of a time pattern in protein S100B 
production. In the stratified analysis (GOS 1-2 vs. GOS 4-5), measurement kinetics 
were analogous in both types of sample, with a recorded rise in concentration 48 
hours after brain damage. This behaviour is similar to that described by other authors 
who postulate that secondary brain damage is responsible for the observed increase 















two hours [15]. However, other investigators have reported maximum protein S100B 
expression at the time of patient admission, which is followed by a decrease in levels 
[34]. The heterogeneity of the brain damage involved in the different series may 
explain these observations and might account for the sometimes conflicting findings 
among different authors. The behaviour of this protein underscores the relevance of 
follow-up of its levels over time as a reflection of secondary brain damage. Similar to 
findings reported in other studies, we observed no differences in protein S100B 
expression according to patient gender, type of brain damage or age [34]. 
 
Prognosis of patients with acute brain damage is particularly relevant in intensive care, 
allowing us to inform the relatives, define the best management strategy and optimize 
resource uti lization. The results of our study indicate that determinations in regional 
samples are no better than determinations in systemic samples for predicting 
unfavourable prognosis or development of brain death. Therefore, although the 
systemic protein levels are lower than in the regional jugular bulb samples, they could 
be used as a diagnostic tool. In the literature, different S100B optimal cutoff points to 
predict outcome can be observed [34,35]. The cutoff points observed in our study are 
similar to those described by other studies, but Egea et al. proposed 0.372 μg/L as the 
24-hour cutoff [36]. We would like to point out that these differences are explained by 
the study design and the type of brain injury. Transcranial gradient upon admission 
may serve as a marker of brain death, but the numbers are small and need to be 
confirmed.  Development of brain death may be associated with damage of greater 
magnitude, i.e. very serious primary brain injuries, and thus to an increased production 
of protein S100B. This increased production is reflected by a significant gradient or 
difference between the regional and peripheral measurements, defining it as a marker 















reported by other authors on relating the measurement of certain markers at the time 
of admission to patient prognosis [24,25] and to increased lesion severity upon 
admission. In this context, and on a speculative basis, secondary brain damage in 
other published series may have been responsible for brain death, and therefore the 
gradient measured after 48 hours may serve as the marker. Our group also detected a 
correlation between measurement after 48 hours and the prognosis in an in vitro 
model of brain damage, using regional serum samples collected on day 2 as apoptotic 
stimulus [37,38]. This again clearly illustrates the importance of the dynamism of brain 
injury and hence of secondary brain damage, and underscores the importance of the 
heterogeneity of the study population when it comes to drawing conclusions. 
Our results show a high gradient upon admission to be associated with more serious 
damage and secondarily to brain death. This observation once more illustrates the 
heterogeneity of the characteristics of acute brain damage that constitutes a challenge 
for conducting studies designed to validate biomarkers for posterior application to 
clinical practice. 
The heterogeneity of patient sample constitutes a limiting factor in our study, in the 
same way as clinical follow-up over 6 months and the measurement of protein S100B 
levels for four days.  
 
Conclusions 
The results obtained can be summarized as follows: 
• Regional protein S100B levels are higher than systemic levels, confirming the 
brain origin of the protein. 
• The time course of protein S100B levels  is analogous in the regional and 















• Transcranial gradient in protein S100B concentration is correlated to the 
development of brain death.  
• Protein S100B may be an early prognostic marker in patients with acute brain 
damage.  
 Peripheral determinations may be used in a clinical setting, given their minimally 
invasive nature and the lack of benefit of jugular bulb determination of S100B 
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Figure 1. Time course of protein S100B determinations at peripheral (CVB) and 
regional level (IJV), and of the transcranial gradient according to subsequent clinical 




Figure 2. ROC curves of the different regional (IJV) and peripheral determinations 
(CVB) referred to prognosis and development of brain death. No differences between 




















Table 1. Characteristics of the study population. 
 
Data are shown as median and interquartile or number and percentage. 
APACHE II: Acute Physiology And Chronic Health Evaluation. GOS: Glasgow  





Table 2. S100B determinations depending on the origin of the samples. 
 
IJV: internal jugular vein; CVB: central venous blood 
Data are shown as median (range interquartile 
 
 
Table 3. Characteristics of the study population according to the prognosis and 
development of brain death. 
 
 
Grad.: gradient (jugular level - systemic level). GCS: Glasgow Coma Score. APACHE 
II: Acute Physiology And Chronic Health Evaluation  Poor prognosis: Glasgow 
Outcome Score 1 to 3 (deceased, vegetative state or severe disability). Good 
prognosis: Glasgow Outcome Score 4 or 5 (moderate disability with good recovery). 





Table 4. Optimum cut-off points for the protein S100B determinations (μg/l). 
 
IJV: internal jugular vein; Grad.: gradient (jugular level - systemic level); CVB: central 

















































Table 1. Characteristics of the study population. 
 
 Total sample (N: 83) 
Age (years) 55 (38 -   68) 
Gender (females) 26 (31.3%) 













APACHE II 17.1 (5.2) 
GCS 6 (4  8) 







Brain death 25 (30.1%) 
GOS after 6 months  1 (1 - 4) 
GOS 1 - 3 (poor prognosis) 61 (73.5%) 
GOS 4 and 5 (good recovery) 22 (26.5%) 
Time injury-ICU (hours) 2.3 (2,1 -  4,3) 
 
Data are shown as median and interquartile or number and percentage. 
APACHE II: Acute Physiology And Chronic Health Evaluation. GOS: Glasgow  

















Table 2. S100B determinations depending on the origin of the samples. 
 
 IJV (μg/l) CVB (μg/l) Gradient  
0 hours    
All patients 
(n: 83) 
0.23  (0.13 - 0,49) 0.21 (0.1 - 0.4) 0.02 (0.004 - 0.06) 
TBI N: 40 0.30 (0.15 - 0.50) 0.25 (0.15 - 0.28) 0.02 (0.01 - 0.09) 
HIC 43 0.19 (0.12 - 0.43) 0.15 (0.10 - 0.34) 0.03 (0.01 - 0.06) 
24 hours  
 All patients 
 (n: 54) 
0.22 (0.13 - 0.47) 0.21 (0.1 - 0.45) 0.02 (0.004 - 0.06) 
TBI (N:28) 0.21 (0.13 - 0.44) 0.20 (0.11 - 0.27) 0.03 (0.005 - 0.06)  
HIC (N:27) 0.31 (0.14 - 0.43) 0.25 (0.11 - 0.51) 0.02  (0.01 - 0.07) 
48 hours  
 All patients 
(n: 54) 
0.15 (0.07 -  0.25) 0.14 (0.07 - 0.27) 0.01 (0.01 - 0.04) 
TBI  (N:28) 0.15 (0.1 - 0.3) 0.14 (0.1 - 0.31) 0.01 (0.02 -  0.04) 
HIC (N:27) 0.14 (0.05 - 0.44) 0.09 (0.07 -  0.23) 0.03 (0.01 - 0.022) 
72 hours  
 Al patients 
(n :24) 
0.11 (0.06 - 0.19) 0.07 (0.03 - 0,15) 0.01 (0.004 - 0.06) 
TBI (N:15) 0.14 (0.10 - 0.26) 0.10 (0.04 - 0.25) 0.01 (0.005 - 0.7) 
HIC (N:9) 0.09 (0.06 - 0.16) 0.06 (0.03  - 0.13) 0.012 (0.006 0.04) 
 
IJV: internal jugular vein; CVB: central venous blood 



















 Table 3. Characteristics of the study population according to the prognosis and 
































Grad.: gradient (jugular level - systemic level). GCS: Glasgow Coma Score. APACHE II:  Acute 
Physiology And Chronic Health Evaluation  Unfavourable outcome: Glasgow Outcome Score 1 
to 3 (deceased, vegetative state or severe disability). Favourable outcome: Glasgow Outcome 
Score 4 or 5 (moderate disability with good recovery). 

























Age (years) 57 (50 -69) 37 (22-53) 0.001 57 (45-69) 53 (37-66) 0.153 
GCS 5 (4 7) 7 (6-9) 0.004 4 (4-5) 7 (5-9) 0.001 
APACHE II 19 (16-21) 12 (10-14) 0.001 19 (17-23) 16 (12-20) 0.002 
S100B Grad 
0 hours  
(μg/l) 




0.05  (0.02- 
0.17) 






0.004 (-0,01 -  
0,04) 
0.03  (0.004 -
0.7) 
0.983 
0.01  (0.04 - 
0.18) 






0.005 (-0.01 -  
0.02) 











0.01 (0.005 - 
0.06) 
0.008  (0.001 - 
0,03) 
0.405 
0.02 (0.003 - 
0.06) 





















Brain death Poor prognosis (GOS 1-3) 
Cut-off pt Sensitivity Specificity Cut-off pt Sensitivity Specificity 
IJV 0 hours 0.72 30.4 96 0.6 17.2 93.8 
IJV 24 hours 1.07 20 94.8 0.63 25.6 100 
IJV 48 hours 0.62 35.71 95.35 0.15 46 64.03 
IJV 72 hours 0.36 11.70 96.43 0.21 23.1 75 
CVB 0 hours 0.75 23.8 98.04 0.26 47.3 76.5 
CVB 24 hours 1.1 12.5 95.12 0.32 43.5 90.9 
CVB 48 hours 0.7 40 95.65 0.3 27.7 92.9 
CVB 72 hours 0.2 16.6 92.86 0.2 12.5 100 
Grad  0 hours 0.32 20 100 -0.02 94.5 31.3 
Grad 24 hours 0.16 27 95 -0.12 100 9 
Grad 48 hours 7.9 10 100 -0.6 93 14.3 
Grad 72 hours 0.12 17 96 -0.03 92.3 25 
 
IJV: internal jugular vein; Grad.: gradient (jugular level - systemic level); CVB: central 



















 Regional protein S100B determinations are higher than systemic determinations, 
confirming the cerebral origin of protein S100B.  
 The transcranial protein S100B gradient is related to the development of brain 
death. 
 S100B  determinations could be used as biomarker of brain damage 
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